PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
| Source: PolyPid Ltd.
Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains
D-PLEX100 Antibacterial Activity Attributed to its Ability to Support High and Prolonged Local Antibiotic Concentration Directly at the Surgical Site
PETACH TIKVA, Israel, June 29, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new publication highlighting the potent antibacterial activity of D-PLEX100 and its potential as an effective prophylactic drug against the most prevalent bacteria causing surgical site infections (SSIs), including resistant strains. The paper, entitled, “Potent antibacterial activity in surgical wounds with local administration of D-PLEX100” was recently published in the European Journal of Pharmaceutical Sciences and can be found here.
“This publication highlights the tremendous potential of D-PLEX100 in addressing the persistent challenge of surgical site infections, especially in an era of increased multidrug-resistant bacteria” stated Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer. “The data showed the significant antibacterial activity of D-PLEX100 in pre-clinical and phase 2 clinical studies against a wide range of bacteria tested, including resistant ones. D-PLEX100’s high anti-bacterial efficacy is attributed to its ability to support high local doxycycline concentration over a prolonged period in the surgical site and confirm its prophylactic potential against a wide range of antibiotic resistant bacteria, addressing a critical need in hospital care.”
The efficacy and safety of D-PLEX100 for the prevention of abdominal colorectal SSIs are currently being further evaluated in the SHIELD II Phase 3 clinical trial. Top-line results are expected in mid-2024.